You can helpexpand this article with text translated fromthe corresponding article in Hebrew. (November 2021)Click [show] for important translation instructions. Machine translation, likeDeepL orGoogle Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. Youmust providecopyright attribution in theedit summary accompanying your translation by providing aninterlanguage link to the source of your translation. A model attribution edit summary isContent in this edit is translated from the existing Hebrew Wikipedia article at [[:he:BriLife]]; see its history for attribution. You may also add the template{{Translated|he|BriLife}} to thetalk page. For more guidance, seeWikipedia:Translation.

BriLife

The formerPresident of Israel,Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of theIsrael Institute for Biological Research, at theBarzilai Medical Center.
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Other names	Brilife
Routes of administration	Intramuscular
ATC code	None
Identifiers
CAS Number	2699603-14-8[1]

Part ofa series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact andrecession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Infected leaders Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

BriLife, also known asIIBR-100, is a replication-competentrecombinantVSVviral vectoredCOVID-19 vaccine candidate.^[2][3][4][5] It was developed by theIsrael Institute for Biological Research (IIBR).^[2][6][7] The IIBR partnered with theUS-based NRx Pharmaceuticals to completeclinical trials and commercialize the vaccine.^[8][9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.^[10][4]

• IIBR-100 entry at Stanford Medicine
• Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Scholia has a profile forBriLife(Q100694835).

Wikimedia Commons has media related toBriLife.

This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it.

• v
• t
• e

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Clinical trials related to COVID-19
• Israeli COVID-19 vaccines
• Science and technology in Israel
• Viral vector vaccines
• Vaccine stubs
• COVID-19 vaccine stubs

• Articles with short description
• Short description is different from Wikidata
• Use dmy dates from April 2021
• Science and technology articles needing translation from Hebrew Wikipedia
• Articles without EBI source
• Chemical pages without ChemSpiderID
• Chemical pages without DrugBank identifier
• Articles without KEGG source
• Articles without InChI source
• Articles without UNII source
• Drugs with no legal status
• Articles containing unverified chemical infoboxes
• Drugs that are a vaccine
• Commons category link is on Wikidata
• All stub articles